The antibody aducanumab reduces Aβ plaques in Alzheimer's disease | Nature
Biogen Reverses Take on Aducanumab Trial Data | MedPage Today
Aduhelm (aducanumab) Q+A - Penn Memory Center
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer's Disease | Biogen
Medicare Finalizes Limits on Aducanumab Coverage | MedPage Today
Aducanumab: will Biogen's Aduhelm recover from its rocky start? - Pharmaceutical Technology
FDA changes prescribing instructions to limit use of contentious Alzheimer's drug amid public backlash | KTLA
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
EMA gives thumbs down to Biogen's Alzheimer's drug aducanumab - Drug Discovery and Development
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies | Biogen
Biogen releases long-term Aduhelm data
Biogen's Alzheimer's Drug Gets FDA Approval, Mixed Reviews | The Scientist Magazine®
Biogen gives up seeking European approval for aducanumab - Drug Discovery and Development
June 7, 2021: A Historic Day | The Long and Winding Road...
Biogen's Aducanumab: A Look at the Drug's History and Recent Updates | BioSpace
Aduhelm safety: the data gap on aducanumab's brain swelling side effect
FDA Approval of a New Alzheimer's Drug Comes With Controversy | Smart News| Smithsonian Magazine
Aducanumab: New Medication FDA Approved for Alzheimer's Disease – Psychiatry Education Forum
Aduhelm (aducanumab) Q+A - Penn Memory Center
Controversial FDA Approval Of Alzheimer's Drug Aducanumab Sets Stage For Possible Medicare Coverage Battle
FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries | KFF
James Deardorff on X: ""Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease" - Hmm... 1. https://t.co/k7Ga4ja0br 2. https://t.co/5cr8gYW72s https://t.co/7NboyUVjWr" / X
With Spotlight on Alzheimer's Disease and Biogen, Competitors' Stocks Soar | BioSpace
Congressional Investigation into Alzheimer's Drug Aduhelm Faults the F.D.A. and Biogen - The New York Times
Congressional Probe of Alzheimer's Drug Approval Finds Fault With FDA Actions | MedPage Today
